Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The presentation will also be available via live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available for 90 days following the presentation.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227427565/en/
Investor Contact:
Nick Smith
investors@altoneuroscience.com
Media Contact:
Jordann Merkert
media@altoneuroscience.com
Source: Alto Neuroscience, Inc.